NCT01815307View on ClinicalTrials.gov

Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

December 31, 2017

Conditions
Biliary Tract Cancer
Interventions
DRUG

Gemcitabine

1000mg/m2, day 1 every 2 weeks

DRUG

S-1

80mg/m2/day, day 1-28, every 6 weeks

Trial Locations (1)

565-0871

Osaka University, Graduate School of Medicine, Osaka

All Listed Sponsors
lead

Kansai Hepatobiliary Oncology Group

NETWORK

NCT01815307 - Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer | Biotech Hunter | Biotech Hunter